Result
MRMP was identified in 43% of the patients tested within March 2013 to
August 2013. No single clinical characteristic or laboratory markers
were reliable in differentiating between MSMP and MRMP. A clinical
parameter of non-defervescence at 72 hours was identified as a good
clinical indicator for likely macrolide resistance. 96% of MSMP
patients achieved defervescence by 72 hours. There were 5 patients that
developed pleural effusion and 80% of them belonged to the MRMP group.
All of the 15 patients treated with doxycycline, were able to achieve
rapid defervescence within 24 hours. The overall length of stay was
longer in the MRMP group.